重组组织型纤溶酶原激活剂静脉溶栓治疗急性脑梗死的临床研究

目的:探讨重组组织型纤溶酶原激活剂(rt-PA)静脉溶栓治疗急性脑梗死(ACI)患者的疗效及安全性。方法:将发病在4.5 h内ACI患者139例,且均符合静脉溶栓适应证,按入院顺序分为rt-PA组(61例)和对照组(ACI)(78例),分别给予rt-PA静脉溶栓和奥扎格雷钠治疗。采用NIHSS及mRS评分比较2组患者治疗后24 h、7 d、90 d的疗效及安全性。结果:rt-PA组治疗后7 d,NIHSS评分较对照组改善更显著。rt-PA组90 d mRS评分优于对照组。2组病死率、症状性颅内出血发生率无统计学差异。结论:ACI患者4.5 h内给予rt-PA静脉溶栓,疗效优于奥扎格雷钠,且较为安全。

Clinical study of thrombolytic therapy with intravenous recombinant tissue-type plasminogen activator for patients with acute cerebral infarction

Objective：To investigate the safety and efficacy of thrombolytic therapy with intravenous recombinant tissue-type plasminogen activator （rt-PA） for patients with acute cerebral infarction （ACI）.Methods：ACI patients within 4.5 hours of stroke onset were involved in the study.The patients were divided into rt-PA group （61 cases） and control group （78 cases）,intravenous rt-PA or Ozagrel Sodium was received respectively.NIHSS and mRS were used to assess and compare the efficacy and safety in two groups 24 hours,7 days and 90 days after treatment.Results：The scores of NIHSS at 7 days,the mRS at 90 days in the rt-PA group were significantly better than those of control group.There were no significant statistical differences in the mortality and the incidence of symptomatic intracranial hemorrhage between the two groups.Conclusion：ACI patients who receive thrombolytic therapy with rt-PA within 4.5 hours after disease onset achieve an effect superior to intravenous Ozagrel Sodium,and it is as safe as intravenous Ozagrel Sodium.